Recent Updates
Recently added Catalysts

APG2575

Phase 1

Waldenstrom Macroglobulinemia | Small molecule | Other |Ascentage Pharma Group International - American Depository Shares|Last Updated: Aug 19, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment46
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04260217APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström MacroglobulinemiaPHASE1 COMPLETED 46 — — May 30, 2021Aug 13, 2025Aug 19, 202514 United States, United States +12
Unlock Drug Trial Details
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
PurposeTREATMENT
Interventions
NameTypeDescription
APG2575 400 mgDRUGAPG2575 400 mg
APG2575 600 mgDRUGAPG2575 600 mg
APG2575 800 mgDRUGAPG2575 800 mg
Unlock Study Design Details